Replimune Group Inc (REPL) - News Archive

In a significant stride towards revolutionizing treatment options for melanoma and hepatocellular carcinoma (HCC), Replimune Group, Inc. (NASDAQ: REPL), a pioneering clinical-stage biotechnology firm dedicated to novel...

NEW YORK, Sept. 18, 2025 The Gross Law Firm has officially reached out to shareholders of Replimune Group, Inc. (NASDAQ: REPL), encouraging those who experienced financial losses to join a class action lawsuit. This leg...

In a significant move aligned with its strategic objectives, Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology firm at the forefront of developing cutting-edge oncolytic immunotherapies, recently anno...

Replimune Group s Strategic Inducement Awards: A Move Towards Workforce Stability Amidst Revenue ChallengesOn April 11, 2025, Replimune Group, Inc. (NASDAQ: REPL), a biotech frontrunner specializing in innovative oncoly...

Replimune Group, Inc. Inducement Grants Overview Replimune Group, Inc. (NASDAQ: REPL), a biotechnology firm engaged in the development of innovative oncolytic immunotherapies, recently issued a press release regarding t...

Replimune Moves Forward with $125 Million Public Offering Amid Regulatory Progress and Financial ChallengesWOBURN, Mass. Nov. 25, 2024 Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company focused...

Replimune Secures Breakthrough Therapy Designation and Applies for Accelerated FDA Approval Amidst Revenue Challenges In a significant move for the biotechnology industry, Replimune Group, Inc. (NASDAQ: REPL), a clinica...

WOBURN, Mass. October 1, 2024 Replimune Group, Inc. (Nasdaq: REPL), an innovative clinical stage biotechnology company committed to developing cutting-edge oncolytic immunotherapies, has made significant strides in the...

Replimune s Strategic Inducement Grants Solidify Commitment to Innovative Oncolytic Immunotherapies On November 8, 2024, Replimune Group, Inc. (NASDAQ: REPL), a pioneering entity in the field of clinical-stage biotechno...

This article reviews the recent announcements by Replimune Group, Inc. a biotechnology company specializing in oncolytic immunotherapies. Specifically, it discusses the company s upcoming participation at two investor c...

Replimune’s RP1 Shows Promise in Anti-PD1 Resistant Melanoma, Sets New Benchmarks Replimune Group Inc made a significant splash at the European Society for Medical Oncology (ESMO) Congress 2024, presenting the primary a...

Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024- Alignment with FDA on accelerated approval pathway for RP1 in anti-PD1 failed melanoma- Share price increases by 11...

In a significant development in the realm of cancer treatment, Replimune Group, Inc. has announced that their late-breaking abstract presenting the primary analysis of the IGNYTE clinical trial has been selected for an...

Replimune Group Inc (NASDAQ: REPL) has recently witnessed a significant surge in its stock performance, surpassing the broader market s gains. This article examines the events that have contributed to Replimune Group s...

In a recent development, Replimune Group Inc, a clinical stage biotechnology company specializing in oncolytic immunotherapies, has taken a significant stride towards strengthening its position in the industry. Led by a...

Replimune s RP1 and Nivolumab Combination Therapy Shows Encouraging 12-Month Overall Response Rate in Anti-PD1 Failed Melanoma Melanoma remains one of the most challenging cancers to treat, with a significant subset of...

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer R...

Replimune Grants Inducement Equity Awards to Key New Executives, Demonstrating Commitment to Growth and InnovationWOBURN, Mass., April 04, 2024 - Replimune Group, Inc. (NASDAQ: REPL), a leading clinical stage biotechnol...

Replimune Announces Leadership Transitions and Strengthened Executive Team as Shares Trade HigherReplimune Group Inc, a renowned biotechnology company specializing in oncolytic immunotherapies, has recently announced si...

Replimune Group Inc., a leading biotechnology company focused on developing innovative oncolytic immunotherapies, recently announced its initial primary analysis results from the CERPASS clinical trial in advanced cutan...